UroGen Pharma Ltd
UroGen Pharma Ltd (URGN) Unusual Options Activity Today
URGN options volume power reached 1x on the previous trading day. The highest reading was on the $40 CALL expiring 2027-01-15.
Read more
Checking URGN unusual options activity helps you spot when traders are making outsized bets on UroGen Pharma Ltd before the broader market catches on. UroGen Pharma Ltd's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor URGN unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching URGN unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking URGN unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and URGN unusual options flow data becomes especially valuable around earnings, product launches, and macro events.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer.
The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Catalysts rarely arrive without a footprint, and URGN unusual options activity is often where that footprint shows up first. Our scanner tracks UroGen Pharma Ltd's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at URGN unusual options volume on the call side or chasing put sweeps, UroGen Pharma Ltd's unusual options flow today is one click away, so put it on your radar before the headlines hit.
| 49.00 | — | 1.15 | 1.15 | 107% | 4 | 5 | 80.00% |
| 46.00 | 0.40 | 1.75 | 1.08 | 83% | 1 | 2 | 50.00% |
| 30.00 | 9.00 | 13.00 | 11.00 | 118% | 0 | 0 | — |
| 33.00 | 6.00 | 10.00 | 8.00 | 89% | 0 | 0 | — |
| 34.00 | 5.40 | 9.50 | 7.45 | 101% | 0 | 0 | — |
| 40.00 | 1.80 | 2.45 | 2.13 | 70% | 4 | 12 | 33.33% |
| 41.00 | 2.20 | 4.50 | 3.35 | 90% | 1 | 17 | 5.88% |
| 30.00 | — | 1.70 | 1.70 | 183% | 0 | 0 | — |
| 33.00 | — | 4.90 | 4.90 | 264% | 0 | 0 | — |
| 34.00 | — | 4.90 | 4.90 | 247% | 0 | 0 | — |
As of September 30, 2026
Spot unusual options activity before it moves
Track URGN options flow across every expiration, filter by volume power, and find the setups with abnormal activity before the trade is gone.
Start your 14-day free trial→